01—Abstract
Summary
Summary of the 8-K filed April 29, 2025. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported financial results for the first quarter ended March 31, 2025, as furnished in Exhibit 99.1 to this Form 8-K.
Total revenues, net were $116.6 milliona, compared with $211.1 million in the prior-year quarter, reflecting a $131.2 million decline in license and services revenue (to $79.9 million, including $75.0 million of regulatory milestone revenue tied to the European Commission's approval of BEYONTTRA) that was partly offset by $36.7 million of first full-quarter U.S. Attruby net product revenue. The company posted a net loss attributable to common stockholders of $167.4 million, or $0.88 per share, versus $35.2 million, or $0.20 per share, a year earlier. Operating costs and expenses rose to $221.0 million, driven by a $40.5 million increase in SG&A to support the Attruby commercial launch.
Balance sheet and financing activity were significant in the quarter. Cash and cash equivalents fell to $540.6 millionb from $681.1 million at December 31, 2024, as net cash used in operating activities of $199.2 million and $459.0 million of term loan repayment, along with $48.3 million of common stock repurchases, outweighed $563.0 million of net proceeds from the issuance of 2031 Notes. The company also stated that its cash balance excludes $105 million in regulatory milestone payments anticipated in the second quarter for ex-U.S. approvals of BEYONTTRA.
Thomas Trimarchi, Ph.D. was appointed President and Chief Financial Officer. On the pipeline, the filing highlights that the FORTIFY (BBP-418, LGMD2I/R9) and CALIBRATE (encaleret, ADH1) Phase 3 studies are fully enrolled with topline readouts expected in the second half of 2025, that PROPEL 3 (infigratinib, achondroplasia) topline results are expected in early 2026, and that a Phase 2 proof-of-principle study of encaleret in hypoparathyroidism showed 78%c of N=9 participants achieving concomitant normal blood and urine calcium within 5 days.
02—Key points
Key Highlights
- Total revenues, net of $116.6 million, down from $211.1 million, as license and services revenue fell to $79.9 million from $211.1 million, including $75.0 million of milestone revenue from the EC approval of BEYONTTRA.
- First full quarter of U.S. Attruby net product revenue of $36.7 million; as of April 25, 2025, 2,072 unique patient prescriptions were written by 756 unique prescribers.
- Net loss attributable to common stockholders of $167.4 million ($0.88 per share), compared with $35.2 million ($0.20 per share) in the prior-year quarter.
- Cash and cash equivalents of $540.6 million at March 31, 2025, down from $681.1 million at year-end 2024, after a $459.0 million term loan repayment and $199.2 million of operating cash outflow.
- Issued $500 million of 1.75% convertible senior notes due 2031 (with an option for an additional $75 million), with net proceeds of approximately $563.0 million, used in part to repay and terminate the term loan.
- Pipeline: FORTIFY and CALIBRATE Phase 3 studies fully enrolled with topline readouts expected in 2H 2025; PROPEL 3 topline expected in early 2026; hypochondroplasia Phase 2 observational run-in fully enrolled ahead of schedule.
- Regulatory: BBP-812 (Canavan disease) alignment with FDA on an Accelerated Approval pathway using urine NAA as a surrogate endpoint; BEYONTTRA approved in the EU, Japan, and UK.
03—Questions
Frequently Asked Questions
Why did revenue decline year over year despite the Attruby launch?
Total revenues, net decreased by $94.5 million to $116.6 million. License and services revenue fell by $131.2 million, as the prior-year quarter primarily reflected recognition of most non-refundable upfront payments under the Bayer and KKC license agreements. This was partly offset by $36.7 million of new Attruby net product revenue.
What drove the increase in operating expenses and the net loss?
Operating costs and expenses rose $10.2 million to $221.0 million. SG&A increased $40.5 million to support Attruby commercialization, including marketing, advertising, and salesforce personnel, and cost of revenues rose $2.0 million. These were partly offset by a $29.5 million decrease in R&D. Total other expense, net increased $28.7 million to $65.2 million, mainly from $18.7 million higher interest expense and a $15.6 million net loss from equity method investments.
How did the company's cash position change, and what does the company say about upcoming cash inflows?
Cash and cash equivalents decreased $140.5 million to $540.6 million. The company attributes this to $199.2 million of operating cash use, $459.0 million of term loan repayment including prepayment fees, and $48.3 million of stock repurchases, partly offset by $563.0 million of net note proceeds. The company stated the balance does not include $105 million in regulatory milestone payments anticipated in Q2 2025 for ex-U.S. approvals of BEYONTTRA.
What are the key pipeline catalysts investors should watch?
The filing identifies topline or interim readouts for BBP-418 (FORTIFY, interim analysis at 12 months, potential Accelerated Approval) and encaleret in ADH1 (CALIBRATE) in the second half of 2025, and PROPEL 3 topline results for infigratinib in early 2026. It also notes the first participant in the ACT-EARLY Phase 3 study is expected to be dosed in 2025 and that the company intends to advance encaleret to a registrational study in chronic hypoparathyroidism in 2026.
04—Continue